Multinational Study Exploring Patients' Perceptions of Side-effects Induced by Chemo-radiotherapy
Overview
Authors
Affiliations
Purpose: We aimed to prospectively assess the incidence, severity and patients' perceptions of side-effects induced by radiotherapy and concomitant weekly cisplatin.
Patients And Methods: This multinational survey included patients with a diagnosis of gynaecological or head and neck cancer scheduled to receive radiotherapy and concomitant weekly cisplatin. Patients completed a questionnaire prior to anti-cancer treatment and after 3 weeks of treatment. Baseline frequency and severity of symptoms were compared to frequency and severity after 3 weeks of treatment, and patients were asked to rank the five most severe symptoms experienced.
Results: An increase in the severity as well as in the mean number of symptoms (18 compared to 24) was observed during treatment. Patients ranked 7 of the 10 most feared baseline symptoms as non-physical, whereas 8 of the 10 most feared symptoms after 3 weeks of treatment were physical. Nausea was ranked as the 5th most severe symptom during treatment, despite 98% of patients receiving antiemetic prophylaxis.
Conclusion: Patients with head and neck cancer or gynaecological cancer suffer from a number of primarily non-physical symptoms before starting combined chemo-radiotherapy. After 3 weeks of treatment patients score 8 of the 10 most feared symptoms as physical. Future trials focusing on the prevention of side-effects in patients receiving radiotherapy and concomitant chemotherapy are highly warranted.
Bylund-Grenklo T, Efverman A Integr Cancer Ther. 2024; 23:15347354241303454.
PMID: 39610327 PMC: 11605737. DOI: 10.1177/15347354241303454.
Efverman A, Kristofferzon M Integr Cancer Ther. 2024; 23:15347354241281329.
PMID: 39300870 PMC: 11418353. DOI: 10.1177/15347354241281329.
Ruhlmann C, Jordan K, Jahn F, Maranzano E, Molassiotis A, Dennis K Support Care Cancer. 2023; 32(1):26.
PMID: 38097904 PMC: 10721706. DOI: 10.1007/s00520-023-08226-z.
Anticancer acumens of three Annona species: a proportional review.
Balkrishna A, Dabhade N, Singh A, Arya V J Cancer Res Clin Oncol. 2023; 149(9):6693-6702.
PMID: 36670184 DOI: 10.1007/s00432-022-04306-5.
Efverman A Integr Cancer Ther. 2022; 21:15347354221132834.
PMID: 36398874 PMC: 9679609. DOI: 10.1177/15347354221132834.